Charles Thivolet1,2, Lucien Marchand3,4, Karim Chikh4,5. 1. Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310, Pierre-Bénite, France. charles.thivolet@chu-lyon.fr. 2. UnivLyon, Inserm, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Oullins, France. charles.thivolet@chu-lyon.fr. 3. Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de Lyon, 69310, Pierre-Bénite, France. 4. UnivLyon, Inserm, INRA, INSA Lyon, Université Claude Bernard Lyon 1, Oullins, France. 5. Department of Biochemistry, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.
Abstract
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some people with long-standing type 1 diabetes, but little is known about the potential impact of this finding on alpha cell function and incretin levels. This study aimed to evaluate whether insulin microsecretion could modulate glucagon and glucagon-like peptide-1 (GLP-1) responses to a mixed meal tolerance test (MMTT). METHODS: Adults with type 1 diabetes onset after the age of 15 years (n = 29) underwent a liquid MMTT after an overnight fast. Insulin microsecretion was defined when peak C-peptide levels were >30 pmol/l using an ultrasensitive assay. Four individuals with recent-onset type 1 diabetes were included as controls. Glucagon and GLP-1 responses were analysed according to C-peptide patterns. RESULTS: We found comparable peak values, Δ0-max levels and AUCs of glucagon and GLP-1 responses in C-peptide-positive participants (n = 9) and C-peptide-negative participants (n = 16) with long-standing diabetes and in participants with recent-onset diabetes (n = 4). Mean glucagon levels, however, differed (p = 0.01). Mean GLP-1 responses were significantly lower according to C-peptide positivity (p < 0.001, ANOVA). Interestingly, GLP-1 levels correlated to glucagon values in C-peptide-positive participants with long-standing diabetes (Pearson's r = 0.915, p = 0.004) and in participants with recent-onset diabetes (p < 0.001) but not in C-peptide-negative participants. CONCLUSIONS/ INTERPRETATION: The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways.
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some people with long-standing type 1 diabetes, but little is known about the potential impact of this finding on alpha cell function and incretin levels. This study aimed to evaluate whether insulin microsecretion could modulate glucagon and glucagon-like peptide-1 (GLP-1) responses to a mixed meal tolerance test (MMTT). METHODS: Adults with type 1 diabetes onset after the age of 15 years (n = 29) underwent a liquid MMTT after an overnight fast. Insulin microsecretion was defined when peak C-peptide levels were >30 pmol/l using an ultrasensitive assay. Four individuals with recent-onset type 1 diabetes were included as controls. Glucagon and GLP-1 responses were analysed according to C-peptide patterns. RESULTS: We found comparable peak values, Δ0-max levels and AUCs of glucagon and GLP-1 responses in C-peptide-positive participants (n = 9) and C-peptide-negative participants (n = 16) with long-standing diabetes and in participants with recent-onset diabetes (n = 4). Mean glucagon levels, however, differed (p = 0.01). Mean GLP-1 responses were significantly lower according to C-peptide positivity (p < 0.001, ANOVA). Interestingly, GLP-1 levels correlated to glucagon values in C-peptide-positive participants with long-standing diabetes (Pearson's r = 0.915, p = 0.004) and in participants with recent-onset diabetes (p < 0.001) but not in C-peptide-negative participants. CONCLUSIONS/ INTERPRETATION: The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways.
Entities:
Keywords:
Incretins; Insulin microsecretion; Pancreatic alpha cells; Type 1 diabetes
Authors: P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta Journal: Diabetologia Date: 2012-09-11 Impact factor: 10.122
Authors: Chantal Mathieu; Bernard Zinman; Joanna Uddén Hemmingsson; Vincent Woo; Peter Colman; Erik Christiansen; Martin Linder; Bruce Bode Journal: Diabetes Care Date: 2016-08-09 Impact factor: 19.112
Authors: Caroline K Kramer; Carla A Borgoño; Paula Van Nostrand; Ravi Retnakaran; Bernard Zinman Journal: Diabetes Care Date: 2013-11-15 Impact factor: 19.112
Authors: Richard A Oram; Angus G Jones; Rachel E J Besser; Bridget A Knight; Beverley M Shields; Richard J Brown; Andrew T Hattersley; Timothy J McDonald Journal: Diabetologia Date: 2014-01 Impact factor: 10.122
Authors: Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin Journal: J Clin Med Date: 2022-06-08 Impact factor: 4.964
Authors: Michael R Rickels; Carmella Evans-Molina; Henry T Bahnson; Alyssa Ylescupidez; Kristen J Nadeau; Wei Hao; Mark A Clements; Jennifer L Sherr; Richard E Pratley; Tamara S Hannon; Viral N Shah; Kellee M Miller; Carla J Greenbaum Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Kitty de Leur; Charlotte Vollenbrock; Pim Dekker; Martine de Vries; Erwin Birnie; Dick Mul; Bruce H R Wolffenbuttel; Joost Groen; Henk-Jan Aanstoot; Lianne Boesten Journal: Diabet Med Date: 2022-01-17 Impact factor: 4.213
Authors: Ernesto Maddaloni; Geremia B Bolli; Brian M Frier; Randie R Little; Richard D Leslie; Paolo Pozzilli; Raffaela Buzzetti Journal: Diabetes Obes Metab Date: 2022-06-28 Impact factor: 6.408
Authors: Guy S Taylor; Kieran Smith; Tess E Capper; Jadine H Scragg; Ayat Bashir; Anneliese Flatt; Emma J Stevenson; Timothy J McDonald; Richard A Oram; James A Shaw; Daniel J West Journal: Diabetes Care Date: 2020-08-03 Impact factor: 19.112